ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ANI PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
ANI PHARMACEUTICALS INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands | $165.39M | $128.24M | $143.57M | $129.13M | $117.16M | $94.08M | $106.89M | $65.62M | $59.22M | $62.62M | – | – | 62.2% | +41.2% |
| Generics and Other | $100.66M | $109.22M | $103.49M | $98.69M | $94.21M | $103.04M | $83.69M | $82.71M | $78.82M | $74.81M | – | – | 37.8% | +6.8% |
| Generics, Established Brands, and Other | – | – | – | – | – | – | – | $91.91M | $88.85M | $100.49M | $89.91M | $102.10M | – | – |
| Rare Disease | – | – | – | – | – | – | – | $56.43M | $49.19M | $36.94M | $41.75M | $29.73M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands | $52.35M | $36.25M | $48.99M | $41.66M | $29.46M | $21.13M | $28.63M | $5.42M | $15.32M | $23.10M | – | – | +77.7% |
| Generics and Other | $36.49M | $40.32M | $33.19M | $35.08M | $38.18M | $48.54M | $24.38M | $32.62M | $30.04M | $28.99M | – | – | -4.4% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands total net revenues | $165.39M | $128.24M | $143.59M | $129.13M | $117.16M | $94.08M | $106.89M | $65.62M | $59.22M | $62.62M | – | – | 62.2% | +41.2% |
| Rare Disease total net revenues | $135.84M | $94.37M | $131.27M | $118.45M | $103.96M | $68.96M | $87.04M | $56.43M | $49.19M | $36.94M | $41.75M | $29.73M | 51.1% | +30.7% |
| Cortrophin Gel | $117.13M | $75.12M | $111.43M | $101.85M | $81.65M | $52.85M | $59.40M | $52.56M | $49.19M | $36.94M | $41.75M | $29.73M | 44.0% | +43.5% |
| Generics and Other total net revenues | $100.66M | $109.22M | $103.47M | $98.69M | $94.21M | $103.04M | $83.69M | $82.71M | $78.82M | $74.81M | – | – | 37.8% | +6.8% |
| Generic pharmaceutical products | $99.05M | $105.40M | $100.76M | $94.38M | $90.30M | $98.68M | $78.60M | $78.22M | $73.96M | $70.22M | $71.83M | $70.59M | 37.2% | +9.7% |
| ILUVIEN and YUTIQ | $18.72M | $19.26M | $19.84M | $16.60M | $22.32M | $16.11M | $27.64M | $3.87M | $0 | $0 | $0 | $0 | 7.0% | -16.1% |
| Brand royalties and other revenues | $17.73M | $21.54M | – | – | $0 | $0 | – | – | – | – | – | – | 6.7% | – |
| Brands | $11.81M | $12.33M | $12.32M | $10.68M | $13.20M | $25.12M | $19.84M | $9.20M | $10.03M | $25.68M | – | – | 4.4% | -10.5% |
| Unapproved Products | $5.70M | $6.30M | $6.50M | $6.00M | $6.10M | $5.50M | $6.00M | $5.50M | $6.80M | $4.10M | $6.00M | $9.20M | 2.1% | -6.6% |
| Other generic revenues | $1.61M | $3.82M | – | – | $3.92M | $4.36M | – | – | – | – | – | – | 0.6% | -59.0% |
| Sales of rare disease pharmaceutical products | – | – | – | – | – | – | – | – | $49.19M | $36.94M | $41.75M | $29.73M | – | – |
| Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services | – | – | – | – | – | – | – | – | $14.88M | $30.28M | – | $31.50M | – | – |
| Total sales of generic and established brand pharmaceutical products, royalties, and other pharmaceuticals services | – | – | – | – | – | – | – | $91.91M | – | – | – | $102.10M | – | – |
| Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services | – | – | – | – | – | – | – | $13.68M | – | – | – | $31.50M | – | – |
| Royalties and other pharmaceutical services | – | – | $2.71M | $4.31M | $3.92M | $4.36M | $5.09M | $4.49M | $4.86M | $4.60M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | $182.40M | $147.12M | $138.04M | $137.43M | $131.65M | $131.83M | – | – |
| Canada | – | – | – | – | – | – | – | – | $0 | $0 | $0 | $0 | – | – |
| International | – | – | – | – | – | – | $8.17M | $1.22M | – | – | $0 | $0 | – | – |
From the segment and revenue-disaggregation notes of Ani Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.